资源 » 参考数据库 » 客户发表文献

至今，GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次，处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果，再次证明GenScript 有能力帮助业内科学家Make research easy.

Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial

Vaccines (Basel). 2023-02; 
Aleksandr V Kudriavtsev, Anna V Vakhrusheva, Nickolay A Kryuchkov, Maria E Frolova, Konstantin A Blagodatskikh, Taras V Ivanishin, Milana Djonovic, Ekaterina A Romanovskaya-Romanko, Anton N Kovalenko, Dmitry A Lioznov, Tatiana G Zubkova, Svetlana V Teplykh, Rodion A Oseshnyuk, Marina A Stukova, Artur A Isaev, Igor V Krasilnikov
Products/Services Used Details Operation
Proteins, Expression, Isolation and Analysis … ) (GenScript, Piscataway, New Jersey, US) that was used in this study. There is a good correlation between PRNT values and the binding inhibition values obtained with GenScript’s … Get A Quote

摘要

关键词

Betuvax-CoV-2, COVID-19, SARS-CoV-2, betulin, clinical trial, subunit vaccine
Article Link >